Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...

MAR001, a first-in-class monoclonal antibody targeting ANGPTL4, demonstrated approximately 53% placebo-adjusted mean reduction in remnant cholesterol and placebo-adjusted mean reduction in ...

Leveraging large-scale human genetics to advance clinical-stage pipeline of first-in-class treatments that target critical, unaddressed and genetically validated causes of cardiometabolic diseases ...

Marea Therapeutics has emerged with $190 million, a mid-stage clinical program and a plan to harness genetics and pioneer “the next frontier” of cardiometabolic medicines. Marea was incubated by Third ...